Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

THE ROLE OF HYPERGLYCEMIA, HYPERINSULINEMIA AND ELEVATED FREE FATTY ACIDS FOR CARDIAC FUNCTION IN PATIENTS WITH TYPE 2 DIABETES – THE HYPERCARD2 STUDY

Next Previous
Trial Profile

THE ROLE OF HYPERGLYCEMIA, HYPERINSULINEMIA AND ELEVATED FREE FATTY ACIDS FOR CARDIAC FUNCTION IN PATIENTS WITH TYPE 2 DIABETES – THE HYPERCARD2 STUDY

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary) ; Insulin suspension isophane
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Acronyms HyperCarD2

    • Most Recent Events

    • 23 Sep 2022 Primary endpoint has not been met (Myocardial diastolic function (Cardiac MRI), as per Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes
    • 23 Sep 2022 Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
    • 23 Sep 2022 Results assessing the effects of empagliflozin on BGS first, and peripheral insulin sensitiv-ity (IS) second, compared to simi lar glycemic control with insulintreatment, presented at the 58th Annual Meeting of the European Association for the Study of Diabetes..
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top